Abstract

The persistence of covalently closed circular DNA (cccDNA) poses a major obstacle to curing chronic hepatitis B (CHB). Here, we used droplet digital PCR (ddPCR) for cccDNA quantitation. The cccDNA-specific ddPCR showed high accuracy with the dynamic range of cccDNA detection from 101 to 105 copies/assay. The ddPCR had higher sensitivity, specificity and precisely than qPCR. The results of ddPCR correlated closely with serum HB core-related antigen and HB surface antigen (HBsAg) in 24 HBV-infected human-liver-chimeric mice (PXB-mice). We demonstrated that in 2 PXB-mice after entecavir treatment, the total cccDNA content did not change during liver repopulation, although the cccDNA content per hepatocyte was reduced after the treatment. In the 6 patients with HBV-related hepatocellular carcinoma, ddPCR detected cccDNA in both tumor and non-tumor tissues. In 13 HBeAg-negative CHB patients with pegylated interferon alpha-2a, cccDNA contents from paired biopsies were more significantly reduced in virological response (VR) than in non-VR at week 48 (p = 0.0051). Interestingly, cccDNA levels were the lowest in VR with HBsAg clearance but remained detectable after the treatment. Collectively, ddPCR revealed that cccDNA content is stable during hepatocyte proliferation and persists at quantifiable levels, even after serum HBsAg clearance.

Highlights

  • Abbreviations cccDNA Covalently closed circular DNA chronic hepatitis B virus (HBV) (CHB) Chronic hepatitis B ddPCR Droplet digital PCR SB Southern blotting hepatitis B surface antigen (HBsAg) Hepatitis B surface antigen hepatitis B core-related antigen (HBcrAg) Hepatitis B core-related antigen HCC Hepatocellular carcinoma PEG-IFN Pegylated interferon alpha-2a virological response (VR) Virological response HBV Hepatitis B virus nucleos(t)ide analogs (NAs) Nucleos(t)ide analogs ETV Entecavir quantitative real-time PCR (qPCR) Quantitative real-time PCR uPAwild/+/SCID + / + mice Severe combined immunodeficiency mice transgenic for the urokinase-type plasminogen activator gene

  • Clinical studies revealed the potential of serum hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) levels as surrogate biomarkers for intrahepatic cccDNA in chronic HBV (CHB) patients, but little information is available regarding the extent to which HBsAg marker reflects the cccDNA content in the liver in the absence of antibody response to HBsAg under immune suppression, as well as the possibility of HBsAg synthesized from integrated HBV DNA needs to be ­considered[6,7,8,9]

  • To discriminate between the relaxed circular DNA and the cccDNA of the HBV genome, we designed the primer to bind the negative strand on one side of the gap, and the probe to bind the same strand on the other side

Read more

Summary

Introduction

Abbreviations cccDNA Covalently closed circular DNA CHB Chronic hepatitis B ddPCR Droplet digital PCR SB Southern blotting HBsAg Hepatitis B surface antigen HBcrAg Hepatitis B core-related antigen HCC Hepatocellular carcinoma PEG-IFN Pegylated interferon alpha-2a VR Virological response HBV Hepatitis B virus NAs Nucleos(t)ide analogs ETV Entecavir qPCR Quantitative real-time PCR uPAwild/+/SCID + / + mice Severe combined immunodeficiency mice transgenic for the urokinase-type plasminogen activator gene. Nucleos(t)ide analogs (NAs) inhibiting viral DNA synthesis are approved antiviral therapies for chronic HBV (CHB) i­nfection[2,3], they cannot eliminate the virus due to the persistence of covalently closed circular DNA (cccDNA) in the hepatocytes. We developed a new assay to quantitate cccDNA content using ddPCR This ddPCR assay could measure cccDNA more accurately and with greater specificity and sensitivity than qPCR. The amount of cccDNA was stable during hepatocyte proliferation, and the amount of cccDNA was shown to be reduced under PEG-IFN treatment in vivo

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.